TB Enzyme's 'Hidden Switch' Revealed, Promising New Drug Target

Stealth Mechanism in Tuberculosis Enzyme Uncovered

Australian scientists have identified a previously unknown 'stealth switch' controlling a key enzyme in Mycobacterium tuberculosis (Mtb). This discovery, published in Communications Biology, could open a new route to treat drug-resistant tuberculosis.

The enzyme ICL2 is essential for Mtb's survival within the human body. Until now, how it turns on and off remained a mystery.

New Allosteric Activation Path Found

Using advanced techniques at the Australian Synchrotron and the National Deuteration Facility, researchers from the University of Melbourne revealed a hidden allosteric site. This site acts like a 'stealth switch' that activates ICL2.

Lead researcher Dr. [Name] stated, "We have found a new regulatory mechanism that was completely invisible to previous methods. This changes our understanding of how TB controls its metabolism."

Background

Tuberculosis kills over 1.5 million people each year. Current treatments face growing resistance, making new drug targets urgent.

ICL2 is critical for TB's ability to survive on fatty acids inside immune cells. Blocking its activation could disable the bacterium.

What This Means

This 'stealth switch' could be a novel target for drugs that shut down TB's survival mechanisms. Because the activation site is unique to mycobacteria, drugs might avoid human side effects.

Dr. [Name] added, "We can now design molecules that lock this switch in the 'off' position. This strategy could bypass existing drug resistance."

The team plans to screen compounds that bind to the newly discovered allosteric pocket. Clinical trials remain years away, but this breakthrough provides a clear molecular roadmap.